The National Comprehensive Cancer Network (NCCN) guidelines recommend neoadjuvant therapy (NACT) as an effective strategy for high‐risk breast cancer subtypes (e.g., triple‐negative or HER2‐positive) [7]. The gene discussed is ERBB2; the disease is breast carcinoma.